Company Profiles

driven by the PitchBook Platform

Carmot Therapeutics

Description

Developer of drugs designed to unlock novel therapeutic target space not currently accessible to conventional small molecule technologies. The company's drugs are made with proprietary Chemotype Evolution technology that helps in the rapid identification of novel drugs through an evolutionary lead-identification paradigm, enabling patients to cure metabolic diseases, cancer and inflammation.

2010

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$10.8M

Latest Deal Amount

$12.8M

Total Amount Raised

Description

Developer of drugs designed to unlock novel therapeutic target space not currently accessible to conventional small molecule technologies. The company's drugs are made with proprietary Chemotype Evolution technology that helps in the rapid identification of novel drugs through an evolutionary lead-identification paradigm, enabling patients to cure metabolic diseases, cancer and inflammation.

Website:

www.carmot.us

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

409 Illinois Street San Francisco, CA 94158United States +1 (510) 828-0102
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Carmot Therapeutics's full profile, request a free trial.

    Carmot Therapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Carmot Therapeutics Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Carmot Therapeutics Investors (6)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    America's Seed FundGovernment000 0000000 0000
    California Institute for Quantitative BiosciencesAccelerator/IncubatorMinority000 0000000 0000
    Leader VenturesLender/Debt ProviderMinority000 0000000 0000
    Michael J. Fox FoundationOther000 0000000 0000
    National Cancer InstituteGovernment000 0000000 0000
    America's Seed Fund Government
    California Institute for Quantitative Biosciences Accelerator/Incubator
    Leader Ventures Lender/Debt Provider
    Michael J. Fox Foundation Other
    National Cancer Institute Government

    Carmot Therapeutics Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    Stig Hansen Ph.DCo-Founder, Chief Executive Officer & Board Member
    Daniel Erlanson Ph.DCo-Founder, Vice President of Chemistry & Board Member
    Roman Dvorak Ph.DVice President of Clinical Development
    Stig Hansen Ph.D Co-Founder, Chief Executive Officer & Board Member
    Daniel Erlanson Ph.D Co-Founder, Vice President of Chemistry & Board Member
    Roman Dvorak Ph.D Vice President of Clinical Development

    Carmot Therapeutics Board Members (5)

    NameRepresentingRoleSinceContact
    Info
    Aetna Trombley Ph.DSelfBoard Member000 0000
    Daniel Erlanson Ph.DCarmot TherapeuticsCo-Founder, Vice President of Chemistry & Board Member000 0000
    Laurence Lasky Ph.DSelfBoard Member000 0000
    Stig Hansen Ph.DCarmot TherapeuticsCo-Founder, Chief Executive Officer & Board Member000 0000
    Timothy Kutzkey Ph.DThe Column GroupManaging Partner000 0000
    Aetna Trombley Ph.D Board Member Self
    Daniel Erlanson Ph.D Co-Founder, Vice President of Chemistry & Board Member Carmot Therapeutics
    Laurence Lasky Ph.D Board Member Self
    Stig Hansen Ph.D Co-Founder, Chief Executive Officer & Board Member Carmot Therapeutics
    Timothy Kutzkey Ph.D Managing Partner The Column Group
    Request full access to PitchBook